TKD Income Statement - Takeda Pharmaceutical Co Ltd

Watchlist Manager

Watchlist

Price: 33.03 EUR 0.06%

Market Cap: €51.8B

T	Takeda Pharmaceutical Co Ltd XMUN:TKD	JP
	DSV A/S F:DS81	DK
	Penguen Gida Sanayi AS IST:PENGD.E	TR
B	Bank of Montreal F:BZZ	CA
	Chikaranomoto Holdings Co Ltd TSE:3561	JP
M	Marriott Vacations Worldwide Corp F:M8V	US
R	Rojana Industrial Park PCL SET:ROJNA	TH
C	Compass Inc NYSE:COMP	US

Financial profile · Q1 FY2027

A diversified pharma platform with durable cash generation and volatile reported earnings

Takeda’s multi-year history shows a diversified pharmaceutical platform that has expanded revenue while sustaining positive operating cash flow. Reported earnings are more volatile than underlying operations because acquisition-related amortization, financing costs, restructuring, and legal items can materially affect results.

What is developing

The June 30, 2026 quarter reinforced operating resilience, but cash conversion weakened as receivables and investment outlays absorbed cash. The broader TTM earnings picture remains distorted by the AMITIZA litigation provision, indicating development in the financial profile rather than a changed business model.

What matters next

Whether operating cash flow recovers as receivables and working-capital outflows normalize while investment spending continues.

Metric	FY2017 Mar 2017	FY2018 Mar 2018	FY2019 Mar 2019	FY2020 Mar 2020	FY2021 Mar 2021	FY2022 Mar 2022	FY2023 Mar 2023	FY2024 Mar 2024	FY2025 Mar 2025	FY2026 Mar 2026
Revenue	1.7T	1.8T	2.1T	3.3T	3.2T	3.6T	4T	4.3T	4.6T	4.5T
Cost of Revenue	(558.8B)	(495.9B)	(651.7B)	(1.1T)	(994.3B)	(1.1T)	(1.2T)	(1.4T)	(1.6T)	(1.6T)
Gross Profit	1.2T	1.3T	1.4T	2.2T	2.2T	2.5T	2.8T	2.8T	3T	2.9T
Operating Expenses	(982B)	(1.1T)	(1.3T)	(1.9T)	(1.9T)	(1.9T)	(2.2T)	(2.4T)	(2.4T)	(2.3T)
Selling, General & Administrative	(619.1B)	(628.1B)	(717.6B)	(964.7B)	(875.7B)	(886.4B)	(997.3B)	(1.1T)	(1.1T)	(1.1T)
R&D	(312.3B)	(325.4B)	(368.3B)	(492.4B)	(455.8B)	(526.1B)	(633.3B)	(728.6B)	(730.2B)	(668.6B)
Depreciation & Amortization	(156.7B)	(122.1B)	(178.6B)	(455.4B)	(421.9B)	(472.9B)	(542.4B)	(518.4B)	(547.6B)	(500.1B)
Other Operating Expenses	106B	3.9B	2.5B	(2.4B)	(114.4B)	(31.3B)	(59.4B)	(93.1B)	(60.2B)	(21.2B)
Operating Income	191.3B	202.8B	183.5B	286.5B	335.7B	545.5B	550.9B	449.4B	560B	663.5B
Net Interest Income (Expense)	(3.4B)	42.5B	(97.1B)	(158.2B)	(234.7B)	(142.6B)	(158.2B)	(196.5B)	(182B)	(325.6B)
Interest Expense	7.6B	10B	48.2B	149B	130.8B	122.4B	117B	119.5B	137.3B	148.1B
Non-Recurring Items	(44.5B)	(28.2B)	41.2B	(189B)	265.2B	(100.3B)	(17.6B)	(200.1B)	(203B)	(480.2B)
Total Other Income	1m	—	—	—	—	1m	—	1m	0	—
Pre-Tax Income	143.3B	217.2B	127.6B	(60.8B)	366.2B	302.6B	375.1B	52.8B	175.1B	(142.4B)
Tax Provision	(27.8B)	(30.5B)	7.5B	105B	9.9B	(72.4B)	(58.1B)	91.4B	(66.9B)	(9.8B)
Income from Continuing Operations	115.5B	186.7B	135.1B	44.3B	376.2B	230.2B	317B	144.2B	108.1B	(152.1B)
Income to Minority Interest	(573m)	178m	112m	(49m)	(166m)	(107m)	(21m)	(130m)	(215m)	(264m)
Net Income	114.9B	186.9B	135.2B	44.2B	376B	230.1B	317B	144.1B	107.9B	(152.4B)
EPS (Diluted)	146.25	237.56	139.82	28.25	238.96	145.87	201.94	92.09	68.36	(96.75)